11:28 AM EDT, 05/02/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Friday that Health Canada has accepted for review a supplemental new drug submission for semaglutide 2.4 mg as a once weekly treatment for people with metabolic dysfunction-associated steatohepatitis.

MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed.

The drug has been accepted for review under Health Canada's priority review policy, Novo said.

The company said semaglutide injection 2.4 mg is approved by Health Canada for chronic weight management and non-fatal myocardial infarction risk reduction in some adults.

Novo shares were rising nearly 5% in recent trading.

Price: 68.67, Change: +3.07, Percent Change: +4.68